Inspire(US:INSP) TMX Newsfile·2026-01-04 13:16Core Viewpoint - Inspire Medical Systems, Inc. is facing legal scrutiny due to allegations of misleading statements regarding the launch and demand for its new Inspire V device, leading to significant financial losses for investors [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [5]. - Following the announcement of these setbacks, Inspire Medical's stock price plummeted over 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [6]. - The company also reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Allegations of Misconduct - The complaint against Inspire Medical alleges that the company and its executives made false and misleading statements about the market demand for the Inspire V device and the steps taken for its successful launch [4]. - Investors were led to believe that demand for the Inspire V was strong, which was contradicted by the subsequent revelations of logistical and demand issues [4]. Group 4: Call for Information - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, and shareholders regarding Inspire Medical's conduct [8].